Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $26.83.

A number of equities analysts recently weighed in on ALMS shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research report on Thursday, November 14th. HC Wainwright cut their price target on Alumis from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Baird R W raised Alumis to a "strong-buy" rating in a research note on Thursday, October 31st. Finally, Robert W. Baird assumed coverage on Alumis in a research note on Thursday, October 31st. They set an "outperform" rating and a $25.00 price target for the company.

Institutional Trading of Alumis

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Alumis in the 3rd quarter valued at $27,000. MetLife Investment Management LLC acquired a new stake in Alumis during the third quarter worth approximately $89,000. Barclays PLC acquired a new stake in shares of Alumis during the 3rd quarter valued at $197,000. Maven Securities LTD acquired a new position in Alumis during the 2nd quarter worth about $332,000. Finally, Towerview LLC increased its position in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after buying an additional 70,000 shares in the last quarter.

Alumis Stock Up 4.4 %

NASDAQ:ALMS traded up $0.38 during mid-day trading on Friday, hitting $9.00. The stock had a trading volume of 101,661 shares, compared to its average volume of 151,580. Alumis has a twelve month low of $7.66 and a twelve month high of $13.53. The firm's 50-day simple moving average is $10.56.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.